Entity
  • Myricx Bio

    Created in 2019
  • BETA

    Trend leader (A+)
    Existing signals make this entity one of the most dynamic startups
  • Social networks

    49 1 4,016 4,016
  • Activities

  • Technologies

  • Entity types

  • Location

    London, UK

    London

    United Kingdom

  • Employees

    Scale: 2-10

    Estimated: 16

  • Engaged corporates

    3
    1 3
  • Added in Motherbase

    3 years, 6 months ago
Description
  • Value proposition

    Developing a new class of ADCs based on NMT inhibition to treat cancer

    We are a UK biotech company focused on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer.

Corporate interactions BETA
Corporate TypeTweets Articles
GSK
GSK
Pharmaceutical, Pharmaceutical Manufacturing
GSK
Pharmaceutical, Pharmaceutical Manufacturing
Other

30 Sep 2024


AstraZeneca
AstraZeneca
Pharmaceutical, Pharmaceutical Manufacturing
AstraZeneca
Pharmaceutical, Pharmaceutical Manufacturing
Other

31 Oct 2023


Sofinnova Partners
Sofinnova Partners
Financial Services
Sofinnova Partners
Financial Services
Capitalistic
Partnership
Not event

19 Feb 2021

21 Nov 2024



Similar entities
Loading...
Loading...
Social network dynamics